Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting
Brief Summary: This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: FAST | Arm Label: Control; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: FAST; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Control
B: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin phosphate, Drug: Metformin | Arm Label: Sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin phosphate; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Comparator: Sulfonylurea; Assigned to Arm(s): Sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea
C: Arm Label: Low-dosage therapy; Type: EXPERIMENTAL; Interventions: Drug: Metformin and Glimepiride (Low Dosage), Drug: Metformin and Vildagliptin (Low Dosage), Drug: Metformin and Insulin Glargine U100 (Low Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage) | Arm Label: Regular-dosage therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin and Glimepiride (Regular Dosage), Drug: Metformin and Vildagliptin (Regular Dosage), Drug: Metformin and Insulin Glargine U100 (Regular Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage) | Intervention Type: DRUG; Name: Metformin and Glimepiride (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Glimepiride (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy
D: Arm Label: IDegAsp U100 BID; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec/insulin aspart | Arm Label: BIAsp U100 BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: biphasic insulin aspart | Intervention Type: DRUG; Name: insulin degludec/insulin aspart; Assigned to Arm(s): IDegAsp U100 BID | Intervention Type: DRUG; Name: biphasic insulin aspart; Assigned to Arm(s): BIAsp U100 BID

Answer: B